Brokerages Set OPKO Health, Inc. (NASDAQ:OPK) PT at $1.55

Shares of OPKO Health, Inc. (NASDAQ:OPK) have received an average rating of “Reduce” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $1.55.

Several analysts have recently issued reports on the company. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Weiss Ratings raised OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th.

OPKO Health Stock Performance

OPK stock opened at $1.18 on Monday. The firm has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.26. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.61. The company has a market capitalization of $891.01 million, a price-to-earnings ratio of -4.37 and a beta of 1.48. The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. OPKO Health’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.10) EPS. As a group, equities analysts anticipate that OPKO Health will post -0.29 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Several large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC raised its holdings in OPKO Health by 2,369.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 114,396 shares during the period. AQR Capital Management LLC grew its position in shares of OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares during the last quarter. Millennium Management LLC increased its stake in shares of OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after purchasing an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of OPKO Health by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock worth $6,642,000 after purchasing an additional 161,394 shares during the last quarter. Finally, Caxton Associates LLP acquired a new position in shares of OPKO Health during the 1st quarter worth about $130,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.